SG10202010429YA - Targeting of cytokine antagonists - Google Patents
Targeting of cytokine antagonistsInfo
- Publication number
- SG10202010429YA SG10202010429YA SG10202010429YA SG10202010429YA SG10202010429YA SG 10202010429Y A SG10202010429Y A SG 10202010429YA SG 10202010429Y A SG10202010429Y A SG 10202010429YA SG 10202010429Y A SG10202010429Y A SG 10202010429YA SG 10202010429Y A SG10202010429Y A SG 10202010429YA
- Authority
- SG
- Singapore
- Prior art keywords
- targeting
- cytokine antagonists
- cytokine
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13306045 | 2013-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202010429YA true SG10202010429YA (en) | 2020-11-27 |
Family
ID=48874233
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201600165WA SG11201600165WA (en) | 2013-07-19 | 2014-07-01 | Targeting of cytokine antagonists |
SG10202010429YA SG10202010429YA (en) | 2013-07-19 | 2014-07-01 | Targeting of cytokine antagonists |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201600165WA SG11201600165WA (en) | 2013-07-19 | 2014-07-01 | Targeting of cytokine antagonists |
Country Status (11)
Country | Link |
---|---|
US (5) | US9732135B2 (en) |
EP (1) | EP3022230B1 (en) |
JP (1) | JP6475712B2 (en) |
KR (1) | KR102305608B1 (en) |
CN (1) | CN105658669A (en) |
AU (1) | AU2014292355B2 (en) |
CA (1) | CA2918119C (en) |
IL (1) | IL243459B (en) |
MX (1) | MX375426B (en) |
SG (2) | SG11201600165WA (en) |
WO (1) | WO2015007520A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104245734B (en) * | 2012-01-20 | 2017-09-05 | 非营利性组织佛兰芒综合大学生物技术研究所 | Targeting mutant α‑helix bundle cytokines |
WO2015007520A1 (en) * | 2013-07-19 | 2015-01-22 | Vib Vzw | Targeting of cytokine antagonists |
WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
EP3998281A1 (en) | 2016-02-05 | 2022-05-18 | Orionis Biosciences BV | Cd8 binding agents |
CA3016849A1 (en) * | 2016-03-07 | 2017-09-14 | Vib Vzw | Cd20 binding single domain antibodies |
CA3016589A1 (en) * | 2016-03-07 | 2017-09-14 | Vib Vzw | Cd20 binding agents and uses thereof |
JP7105200B2 (en) | 2016-05-13 | 2022-07-22 | オリオニス バイオサイエンシズ ビーブイ | Targeted mutant interferon-beta and its uses |
EP3455245A2 (en) * | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
CA3040802A1 (en) | 2016-10-24 | 2018-05-03 | Orionis Biosciences Nv | Targeted mutant interferon-gamma and uses thereof |
US10906985B2 (en) | 2017-02-06 | 2021-02-02 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
MX2019009255A (en) | 2017-02-06 | 2019-11-05 | Orionis Biosciences Nv | Targeted chimeric proteins and uses thereof. |
WO2018146074A1 (en) | 2017-02-07 | 2018-08-16 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
EP3665201A4 (en) * | 2017-08-09 | 2021-06-02 | Orionis Biosciences, Inc. | Cd8 binding agents |
CN111328286B (en) | 2017-08-09 | 2024-08-23 | 奥里尼斯生物科学有限公司 | PD-1 and PD-L1 binding agents |
KR102793204B1 (en) | 2017-08-09 | 2025-04-08 | 오리오니스 바이오사이언시스 인코포레이티드 | Clec9a binding agents and use thereof |
US20200354424A1 (en) | 2018-01-26 | 2020-11-12 | Orionis Biosciences, Inc. | Xcr1 binding agents and uses thereof |
US11896643B2 (en) | 2018-02-05 | 2024-02-13 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
EP3833391A4 (en) | 2018-08-08 | 2022-08-10 | Orionis Biosciences, Inc. | SIRP1alpha TARGETED CHIMERIC PROTEINS AND USES THEREOF |
CN111499718B (en) * | 2019-01-30 | 2022-06-14 | 复旦大学 | Human alpha interferon receptor binding-related site mutants and uses thereof |
US12351614B2 (en) | 2019-03-28 | 2025-07-08 | Orionis Biosciences, Inc. | CLEC9A-based chimeric protein complexes |
JP7689079B2 (en) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ,インコーポレイテッド | Therapeutic interferon alpha 1 protein |
CN114173784B (en) | 2019-07-18 | 2023-12-01 | 埃尼奥制药公司 | Method for reducing side effects of interferon |
WO2022200525A1 (en) | 2021-03-26 | 2022-09-29 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
US20240392008A1 (en) | 2021-06-09 | 2024-11-28 | Innate Pharma | Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
EP4573110A1 (en) | 2022-08-18 | 2025-06-25 | Regeneron Pharmaceuticals, Inc. | Interferon proproteins and uses thereof |
WO2024238415A1 (en) | 2023-05-12 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Interferon receptor antagonists and uses thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69007975T2 (en) | 1989-08-22 | 1994-07-21 | Immunex Corp | FUSION PROTEIN CONSISTING OF GM-CSF AND IL-3. |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
US6001973A (en) * | 1996-04-26 | 1999-12-14 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
MXPA02001417A (en) * | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Multiple cytokine-antibody complexes. |
US20020193569A1 (en) | 2001-06-04 | 2002-12-19 | Idec Pharmaceuticals Corporation | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
CA2585549A1 (en) | 2004-11-18 | 2006-05-26 | Vib Vzw | Novel type leptin receptor antagonist |
WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
ES2435846T3 (en) * | 2005-06-29 | 2013-12-23 | Yeda Research And Development Co. Ltd. | Interferon alpha 2 (IFN alpha 2) mutants recombinant |
CA2693326A1 (en) | 2006-08-02 | 2008-02-07 | Mcgill University | Gm-csf and il-15 fusokines and methods for modulation of the immune response |
WO2008124086A2 (en) | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
CN101743249B (en) * | 2007-05-11 | 2017-08-08 | 阿尔托生物科学有限公司 | Fusion molecule and the variants of IL 15 |
US20110038865A1 (en) | 2007-06-26 | 2011-02-17 | University Of Miami | Antibody- endostatin fusion protein and its variants |
MX2010003099A (en) | 2007-09-21 | 2010-05-17 | Univ California | Targeted interferon demonstrates potent apoptotic and anti-tumor activities. |
US20110224407A1 (en) * | 2008-09-09 | 2011-09-15 | University Of Medicine And Dentistry Of New Jersey | Type I Interferon Antagonists |
WO2010036918A2 (en) | 2008-09-26 | 2010-04-01 | University Of Massachusetts | Intracellular dna receptor |
BRPI0923346A2 (en) | 2008-12-08 | 2017-07-11 | Complix Nv | SINGLE CHAIN ANTIPARALLEL SUPERHELIC PROTEINS |
JP5764127B2 (en) | 2009-08-17 | 2015-08-12 | ロシュ グリクアート アーゲー | Targeted immunoconjugate |
WO2011029870A1 (en) | 2009-09-10 | 2011-03-17 | Cytos Biotechnology Ag | Use of interleukin-1 beta mutein conjugates in the treatment of diabetes |
EP2718457A4 (en) | 2011-06-06 | 2014-12-24 | Immungene Inc | Engineered antibody-tnfsf member ligand fusion molecules |
EP3559049B1 (en) | 2011-10-28 | 2025-06-11 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
CN104245734B (en) * | 2012-01-20 | 2017-09-05 | 非营利性组织佛兰芒综合大学生物技术研究所 | Targeting mutant α‑helix bundle cytokines |
DK2822575T3 (en) | 2012-03-03 | 2020-06-15 | Immungene Inc | MANIPULATED, MUTERATED ANTIBODY-INTERFERON FUSION MOLECULES |
WO2015007520A1 (en) * | 2013-07-19 | 2015-01-22 | Vib Vzw | Targeting of cytokine antagonists |
-
2014
- 2014-07-01 WO PCT/EP2014/063976 patent/WO2015007520A1/en active Application Filing
- 2014-07-01 US US14/905,348 patent/US9732135B2/en active Active
- 2014-07-01 CN CN201480040656.4A patent/CN105658669A/en active Pending
- 2014-07-01 SG SG11201600165WA patent/SG11201600165WA/en unknown
- 2014-07-01 KR KR1020167002677A patent/KR102305608B1/en active Active
- 2014-07-01 AU AU2014292355A patent/AU2014292355B2/en active Active
- 2014-07-01 EP EP14734166.3A patent/EP3022230B1/en active Active
- 2014-07-01 JP JP2016526507A patent/JP6475712B2/en active Active
- 2014-07-01 SG SG10202010429YA patent/SG10202010429YA/en unknown
- 2014-07-01 CA CA2918119A patent/CA2918119C/en active Active
- 2014-07-01 MX MX2016000721A patent/MX375426B/en active IP Right Grant
-
2016
- 2016-01-04 IL IL24345916A patent/IL243459B/en active IP Right Grant
-
2017
- 2017-07-06 US US15/642,989 patent/US10072059B2/en active Active
-
2018
- 2018-06-14 US US16/008,695 patent/US20180334489A1/en not_active Abandoned
- 2018-06-14 US US16/008,686 patent/US10947288B2/en active Active
-
2021
- 2021-02-09 US US17/171,433 patent/US20210238247A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2015007520A1 (en) | 2015-01-22 |
US20160159875A1 (en) | 2016-06-09 |
CN105658669A (en) | 2016-06-08 |
JP6475712B2 (en) | 2019-02-27 |
IL243459B (en) | 2019-10-31 |
MX375426B (en) | 2025-03-06 |
US9732135B2 (en) | 2017-08-15 |
JP2016529232A (en) | 2016-09-23 |
CA2918119C (en) | 2022-11-29 |
AU2014292355B2 (en) | 2019-08-01 |
IL243459A0 (en) | 2016-03-31 |
EP3022230B1 (en) | 2019-11-06 |
CA2918119A1 (en) | 2015-01-22 |
EP3022230A1 (en) | 2016-05-25 |
US20180334489A1 (en) | 2018-11-22 |
US10072059B2 (en) | 2018-09-11 |
US10947288B2 (en) | 2021-03-16 |
SG11201600165WA (en) | 2016-02-26 |
AU2014292355A1 (en) | 2016-02-04 |
KR20160108292A (en) | 2016-09-19 |
US20180334488A1 (en) | 2018-11-22 |
MX2016000721A (en) | 2016-09-07 |
KR102305608B1 (en) | 2021-09-28 |
US20180057555A1 (en) | 2018-03-01 |
US20210238247A1 (en) | 2021-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL243459B (en) | Targeting of cytokine antagonists | |
IL287516A (en) | Therapeutic uses of empagliflozin | |
IL243479A0 (en) | Novel quinazolinones as bromodomain inhibitors | |
IL241101B (en) | Therapeutic uses of empagliflozin | |
SG11201601493UA (en) | Atomizer | |
SG11201510297QA (en) | Targeted integration | |
IL241102B (en) | Therapeutic uses of empagliflozin | |
SG11201510215VA (en) | Injector | |
AU355193S (en) | Injector | |
LT2981271T (en) | Therapeutic uses of empagliflozin | |
ZA201604502B (en) | Use of benzimidazole-proline derivatives | |
ZA201602831B (en) | Use of lactones | |
HUP1300139A2 (en) | Phenoxypiperidine h3 antagonists | |
IL244537A0 (en) | Novel delivery compositions and methods of using same | |
PL3049378T3 (en) | Preparation of radioiodinated 3-fluoropropyl-nor-beta-cit | |
GB201319437D0 (en) | Delivery of drugs | |
TWM475821U (en) | Structure of mosquito-catch | |
GB201318284D0 (en) | Construction of surfaces | |
PL3071575T3 (en) | Preparation of normorphinans | |
TWM475524U (en) | Structure of rivet-pulling | |
GB201304608D0 (en) | BenTime of Yisrael operable arrangement | |
TWM475672U (en) | Improved structure of signage | |
AU355233S (en) | Injector | |
GB201315211D0 (en) | Hand-held nebuliser |